文献速递痛风与晶体性关节病

培戈洛酶联合免疫调节药物治疗的真实世界有效性

Real-World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-06-23

基于美国风湿病学会风湿病信息学有效性系统登记库2016年1月至2020年6月的回顾性分析,纳入700例接受培戈洛酶治疗的痛风患者。合并使用免疫调节药物者培戈洛酶停药风险降低,免疫调节药物起始者的校正风险比为0.52(95%CI 0.37-0.75),实验室异常不常见且未因合并免疫调节治疗而升高。

要点

  • 合并免疫调节药物起始者培戈洛酶停药风险降低,校正HR为0.52(95%CI 0.37-0.75)。
  • 已使用免疫调节药物者停药校正HR为0.69(95%CI 0.42-1.16),未达统计学显著。
  • 实验室异常不常见(<5%),合并免疫调节药物治疗者未更高。

核心结论

  • 与临床试验一致,这项大型观察性登记库结果提示合并免疫调节药物治疗可改善培戈洛酶的持续性。

研究设计与样本

  • 回顾性分析美国风湿病学会风湿病信息学有效性系统登记库2016年1月至2020年6月的痛风患者。
  • 首次培戈洛酶输注定义为索引日期,按合并免疫调节药物情况分为三组:免疫调节药物起始者(索引日期±60天内起始免疫调节药物处方)、已使用免疫调节药物者(索引日期前>60天已首次开具免疫调节药物处方且在索引日期±60天内至少有一张处方)、未使用免疫调节药物者。
  • 共纳入700例培戈洛酶接受者:免疫调节药物起始者91例、已使用免疫调节药物者33例、未使用者576例,中位随访14个月。

主要发现

  • 合并免疫调节药物者更不易停用培戈洛酶。
  • 免疫调节药物起始者培戈洛酶停药的校正风险比为0.52(95%CI 0.37-0.75)。
  • 已使用免疫调节药物者培戈洛酶停药的校正风险比为0.69(95%CI 0.42-1.16)。
  • 索引日期后180天内实验室异常不常见(<5%),合并免疫调节药物治疗者未更高。

关键数值与推荐

  • 血清尿酸水平≤6 mg/dL为达标阈值。
  • 实验室异常定义包括:白细胞计数<3.4×10^9/L、血小板计数<135,000、血细胞比容<30%、丙氨酸氨基转移酶或天冬氨酸氨基转移酶≥1.5倍正常值上限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to ascertain pegloticase persistence and adverse events associated with concomitant immunomodulatory drug treatment in patients with gout. METHODS: We conducted a retrospective analysis of patients with gout using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry from January 2016 through June 2020. The first pegloticase infusion defined the index date. Based on concomitant immunomodulatory drug treatment, we identified three exposure groups: (1) immunomodulatory drug initiators (patients initiating an immunomodulatory prescription ±60 days from the index date), (2) prevalent immunomodulatory drug recipients (patients receiving their first immunomodulatory drug prescription >60 days before the index date with at least one prescription within ±60 days of the index date), and (3) immunomodulatory nonrecipients (patients receiving pegloticase without concomitant immunomodulatory drugs). We calculated the proportion of patients who achieved serum urate levels ≤6 mg/dL and who had laboratory abnormalities (white blood cell count <3.4 x 109/L, platelet count <135,000, hematocrit level <30%, alanine aminotransferase or aspartate aminotransferase level ≥1.5 times the upper limit normal value) within 180 days after the index date. Cox regression analyzed time to pegloticase discontinuation, controlling for potential confounders. RESULTS: We identified 700 pegloticase recipients (91 immunomodulatory drug initiators, 33 prevalent immunomodulatory drug recipients, and 576 nonrecipients), with a median follow-up of 14 months. Immunomodulatory drug recipients were less likely to discontinue pegloticase. The adjusted hazard ratios of pegloticase discontinuation associated with concomitant immunomodulatory drug initiation and prevalent treatment were 0.52 (95% confidence interval [CI] 0.37-0.75) and 0.69 (95% CI 0.42-1.16), respectively. Laboratory abnormalities were uncommon (<5%) and were not higher in concomitant immunomodulatory drug treatment. CONCLUSION: Consistent with clinical trials, results from this large observational registry suggest that concomitant immunomodulatory drug treatment improves pegloticase persistence.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Holladay EE, Mudano AS, Xie F, et al. Real-World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care Res (Hoboken). 2024. PMID: 38719773. doi:10.1002/acr.25361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。